Share Twitter LinkedIn Facebook Email Eunice Wang, MD, talks about what we’ve learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients at the 2018 Annual Meeting.
Molecular Changes and Patient Stratification – Parrish Phimes, MD Acute Myelogenous Leukemia 2 Mins Read
Inequities in AML Outcomes: Comprehensive Discussion by Pramilla Krishnamurthy Acute Myelogenous Leukemia 2 Mins Read